TNFSF13B and sarcoidosis: This concept is suggested by findings of increased B-cell activating factor (BAFF) serum concentrations in sarcoidosis patients correlating with disease activity and with case series of refractory disease responsive to B-cell depleting therapy (Rituximab) [38, 39].